

## News & Views

### Industry News (Jan 2024 to May 2024)

Flora Wang<sup>1</sup>

<sup>1</sup>ISoOR Insight Team

#### **Organoid Data Facilitates IND Clearance for PD-1 Knockout T Cell Therapy**

January 23, 2024

MedGenCell, a biotech specialized in cell therapy has received approval for its Investigational New Drug (IND) application for a PD-1 gene-edited T cell therapy (IND number: CXSL2300758). The product is an autologous T cell preparation with PD-1 gene knockout, intended for patients aged 18 to 75 with advanced non-small cell lung cancer (NSCLC). Key data in IND package include organoid based drug efficacy data provided by AimingMed, one of the leading organoid companies in China.

#### **MIMETAS Participates in the GRIPonMASH Program for Organ-on-a-Chip Disease Modeling**

February 5, 2024

MIMETAS, a global leader in the field of organ-on-a-chip disease modeling, has participated in the GRIPonMASH initiative. The GRIPonMASH program is dedicated to transforming the detection and treatment of metabolic dysfunction-associated liver disease (MAFLD). MIMETAS is responsible for developing and providing organ-on-a-chip-based disease models to improve the prevention and care of metabolic dysfunction-associated fatty liver disease (MASH).

#### **Autologous EpCAM Targeting CAR-T Enter Clinical Trial with Organoid Data**

February 23, 2024

Immunofoco announced that its self-developed autologous CAR-T cell product targeting EpCAM (IMC001) has received approval from the China Center for Drug Evaluation (CDE) for clinical trials and has subsequently obtained a clinical research permit from the Food and Drug Administration (FDA). In the development process of this product, the organoid company D1Med provided organoid model for evaluation.

### **World Organoid Research Day+ 2024: A Gathering of Top Experts**

February 27, 2024

The “World Organoid Research Day+ 2024” conference was held at the Hinkston Hall Conference Centre in the UK. The event brought together leading experts in the fields of organoids and organs-on-chips to share their latest research findings and advancements. The conference covered a range of topics including organoid development, disease modeling, and regenerative medicine.

### **DarkJade Sciences Completed Pre-A Financing Round with Notable Investors**

February 27, 2024

DarkJade Sciences, a leading international developer of organoid intelligent equipment and chips, has completed its Pre-A round of financing. This round of funding is mainly used for equipment production, registration filing as well as market expansion, initiating the construction of production bases, and accelerating the promotion of multiple innovative product lines.

### **Luohua Biotech Secures A-Round Funding for Organ-on-a-Chip Technology Innovation**

March 1, 2024

Luohua Biotech (Suzhou) has successfully completed a Series A financing round worth tens of millions of yuan. The funds will be used for the intelligent and standardized development of organoid chip technology, providing one-stop solutions for customers. Additionally, Luohua Biotech aims to develop more biomimetic drug testing models in fields such as oncology, nephrology, hepatology, dermatology, genetic diseases, and rare diseases.

### **NextGen Basel 1: Exploring 3D Chip Technology for Safety and Efficacy Assessment**

March 1, 2024

On March 1st, the “NextGen Basel 1” themed conference was held at the Basel Technology Park in Switzerland. The conference covered topics such as “Safety and Efficacy Assessment of Multi-Organ Chips” and “3D Vascular Chips for Assessing Vascular Toxicity”.

### **Beijing Nuoshan Tech Completes Angel Financing with SEE FUND Investment**

March 4, 2024

Beijing Nuoshan Tech has completed a 10 million RMB angel round of financing. This round of financing was exclusively invested by Infinite Fund SEE FUND, and the funds will be used for preclinical research

of the company's fully functional microfluidic organoid chip.

### **Regenerative Bio and Signet Therapeutics Sign Strategic Collaboration Agreement**

March 6, 2024

Regenerative Bio and Signet Therapeutics have officially signed a strategic cooperation agreement. Signet Therapeutics will use its organoid technology platform, particularly focusing on heart and ovarian organoids, to provide research cooperation services for Regenerative Bio's RevOrgan anti-aging intervention ingredient discovery and efficacy evaluation.

### **STEMCELL Technologies Organized “ORGANOID DAY 2024” at NTU: Exploring Organoid Advances**

March 7, 2024

STEMCELL Technologies hosted the “ORGANOID DAY 2024” conference at Nanyang Technological University of Singapore, which brought together top experts, researchers, and industry professionals in the field of organoid research to explore the latest advancements and applications of organoid models.

### **2024 Organoids Conference & ISoOR 2024 Summit: A Successful Multidisciplinary Event in Shanghai**

March 7-8, 2024

The ISoOR 2024 International Organoids Summit were successfully held in Shanghai. The conference was co-hosted by the International Society for Organoids Research (ISoOR), BionGroup, the Greater Bay Area Institute of Precision Medicine (Guangzhou), and Shanghai Jiao Tong University School of Medicine Songjiang Research Institute. It covered themes such as “Organoids and Materials Science”, “Organoids and Drug Development”, and “Interdisciplinary Applications of Organoids”. It provided a specialized academic platform for organoids researchers and individuals from all walks of society interested in the field of organoids.

### **Qijia Biotech Opening Ceremony and Strategic Partnerships**

March 26, 2024

Qijia Biotech officially opened for business. At the opening ceremony, Qijia Biotech signed strategic cooperation agreements with partners such as EverPro Medical and other partner organizations. Qijia Biotech is the world's first one-stop supplier of iPS-derived micro-organ products and technical services.

With its unique iPS lineage differentiation technology, it has fully expanded the traditional organoid model in terms of lineage, structure, and function, and has revolutionarily brought the next-generation micro-organ (iORGAN) to the market. The company is committed to providing systematic solutions for scientific research, drug development, and precision medicine.

### **Successful Conclusion of 2024 American Association for Cancer Research (AACR) Annual Meeting**

April 5-10, 2024

The 115th AACR was held in San Diego, USA. It attracted over 22,500 experts, including researchers, clinicians, and representatives from biopharmaceutical companies. Participants shared their latest advances in cancer research. Notably, 161 posters related to organoid technology were presented, highlighting the growing recognition and application of organoids in academia, industry, and medical institutions.

### **Tumor Organoid Drug Sensitivity Assay included in consensus on Refractory Lung Cancer**

April 12, 2024

The Chinese expert consensus on refractory lung cancer has been published in the Chinese Journal of Tuberculosis and Respiratory Medicine, the official journal of the Chinese Medical Association (CJTARM). This consensus provides a robust framework for the diagnosis and treatment of refractory lung cancer. Notably, for the first time, it includes patient-derived organoid (PDO) drug sensitivity testing to enhance clinical diagnosis and treatment strategies.

### **OSC 2024: The 3rd Organoid Conference**

April 19-21, 2024

The 3rd OSC 2024 Conference on Organoid Standardization and the Guangdong-Hong Kong-Macao Conference on Medical-Industrial Integration of Organoid and Organ Chip, hosted by the Guangdong Association of Precision Medicine Application, took place at the Tsinghua University Research Institute in Shenzhen, China. The conference focused heavily on the development of organoid and organ chip technology.

### **Seminar on the Application of 3D Cell Organoids and High-Content Imaging Technology**

April 23, 2024

Molecular Devices hosted a seminar on the application of 3D cell organoids and high-content imaging technology. The seminar explored the progress in 3D cell and organoid research and the application of high-content imaging technology in these fields.

### **The ODC Committee Hosted an Organoid Industry Conference**

April 24, 2024

The ODC Committee hosted an organoid industry conference themed “The Next Normal: Living With Organoids”. The event was held simultaneously in Vietnam and South Korea and aimed to expand the scope and significance of organoid research.